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Abstract
Background: Information regarding outcome of dogs undergoing surgical manage-
ment for insulinoma is based on studies of a small number of dogs.
Objectives: To report the outcomes of dogs undergoing surgery as treatment for
insulinoma, the prevalence of postoperative diabetes mellitus (DM) in this group and
to determine if development of DM can be predicted.
Animals: Forty-eight client-owned dogs, with a histopathological diagnosis of
insulinoma, from three European referral hospitals.
Methods: Retrospective observational study. Dogs were identified from a search of
electronic hospital records. Cox's regression was used to determine factors associ-
ated with postoperative survival and relapse, and logistic regression was used to
determine factors associated with the development of DM.
Results: Median survival time (MST) was 372 days (range 1-1680 days), with dogs
with stage I disease having the longest survival time. Stage I dogs had MST of
652 days (range 2-1680 days), whereas dogs with either stage II or III disease had
MST of 320 days (range 1-1260 days; P = 0.045). Postoperative hyperglycemia was
identified in 33% (16/48) of the dogs, of which 9 (19% of the total population) devel-
oped persistent DM. No factors that could be used as predictors for development of
DM were identified.
Conclusions and clinical importance: Stage of disease and postoperative hypoglyce-
mia were associated with greater odds of relapse and decreased survival time; these
could be used when discussing prognosis. In this study, postoperative DM developed
more commonly than previously reported, but no factors were identified that might
be useful predictors.
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1 | INTRODUCTION
Insulinoma is the most common endocrine pancreatic tumor in dogs.1,2
Neoplastic beta cells are capable of producing and releasing insulin
independently of blood glucose,3 leading to hyperinsulinemia and
hypoglycemia, that can be life-threatening. Clinical signs result from
neuroglycopenia and increased insulin antagonistic counterregulatory
hormone production.4,5 Insulinomas are usually malignant and they are
thought, in almost all dogs, to have metastasized at the time of
diagnosis,1 although visible metastases are found in only approximately
50% of cases at surgery.6 The common sites of metastasis are regional
lymph nodes, liver, and lungs, with less common sites including
the spleen, mesentery, gastrointestinal tract, kidney, spinal cord, and
bone.2,7,8
Surgical management is the treatment of choice and involves
partial pancreatectomy to remove the primary tumor and any visible
metastases, with longer median survival times in dogs treated surgi-
cally compared to dogs treated medically.9,10 In 2 studies, the
median survival time of dogs undergoing partial pancreatectomy was
381 days and 785 days, respectively, 9,10 compared with 74 days
and 196 days, respectively, in those treated with medical treatment
alone. 9,10 As a result, surgical management is often rec-
ommended11,12 for dogs with World Health Organization (WHO)
stage I (local disease confined to the pancreas) or stage II disease
(presence of locoregional metastasis). Medical management is con-
sidered for nonsurgical candidates such as those with the presence
of distant metastasis, a large pancreatic mass, proximity of the pan-
creatic mass to the pancreatic blood supply, important comorbidity
or when the owner declines surgery.13
A common postoperative complication with partial pancreatec-
tomy is pancreatitis.13 Diabetes mellitus (DM) can also occur and is
thought to develop because of atrophy of the nonneoplastic pan-
creatic beta cells secondary to chronic hyperinsulinemia. Some
dogs develop transient hyperglycemia, whereas a smaller number
of dogs develop persistent DM requiring long-term administration
of insulin.1 In human medicine, prevalence of postpancreatectomy
DM varies from 5 to 78% depending on the heterogeneity of the
population studied.14 The largest study revealed a median preva-
lence of 23%.15 Factors that affect the development of DM after
pancreatectomy in people are: age, pancreatic resection type, re-
section volume ratio, and high body mass index.14. Approximately
10% of dogs develop DM after pancreatectomy,7 with clinical
signs generally occurring when 80%-90% of pancreatic tissue is
excised.16,17
Given the limited information on factors associated with post-
surgical outcome in dogs with insulinoma, the aims of this were to
report the outcomes in a group of dogs undergoing surgical manage-
ment of insulinoma, and to determine the prognostic factors associ-
ated with survival. A further aim was to report the prevalence of
persistent DM in this group and to determine if the development of
DM could be predicted by pre-, peri- or post-operative factors. In
this respect, we hypothesized that DM would be common, as it is in
human medicine.
2 | MATERIALS AND METHODS
2.1 | Study design and ethics
This was a retrospective observational study examining factors associ-
ated with survival in dogs with histologically confirmed insulinoma.
The study was approved by the University of Liverpool Research
Ethics Committee (VREC659), and all owners gave written consent.
2.2 | Case identification and eligibility criteria
Eligible dogs were identified from a search of electronic hospital
records at 3 European referral hospitals; institution 1 was The Small
Animal Teaching Hospital, University of Liverpool, Neston, UK; insti-
tution 2 was Willows Veterinary Centre & Referral Service, Solihull,
UK; and institution 3 was Centro Specialistico Veterinario, Milan, Italy.
Cases seen from November 2004 to June 2017 were identified. To be
eligible for inclusion, dogs had to have clinical signs consistent with
hypoglycemia, and clinical investigations suggestive of insulinoma
including normal or increased serum insulin concentration at the time
of hypoglycemia, low serum fructosamine concentration, increased
insulin: glucose ratio, and a pancreatic mass identified on diagnostic
imaging. In addition, dogs had to have had thoracic and abdominal
imaging and undergone abdominal surgery to excise a pancreatic
mass, confirmed to be insulinoma on subsequent histological and, in
some cases, immunohistochemical examination. Dogs that were dia-
betic before developing insulinoma were excluded given that one of
the aims of the study was to identify the prevalence of postoperative
DM. Additionally, complete clinical records had to be available in
order to determine postoperative outcome.
2.3 | Data collection
Data gathered from medical records included signalment (age, sex,
neuter status, weight, and breed), clinical signs at the time of presen-
tation and clinicopathological investigations (including complete blood
count, serum biochemistry, glucose concentration, fructosamine, and
serum insulin concentration). The preoperative diagnostic imaging
findings, one or more of radiography, ultrasonography, and computed
tomography (CT) reports generated by a specialist in veterinary diag-
nostic imaging were reviewed, and the presence of a pancreatic mass
or lesion consistent with metastatic disease were noted. The reports
were generated at the time each dog had diagnostic imaging
(radiographs and ultrasound or CT), at which time the diagnostic
imager had access to the history of the dog and the suspected diagno-
sis that is, they were not blinded. Surgical reports were reviewed and
compared with the preoperative imaging findings. The histopathology
reports, generated by a specialist in veterinary anatomical pathology,
of the primary tumor and possible metastatic lesions were reviewed,
as well as the records of hospitalization until the time of discharge.
The histopathology reports were generated at the time of the
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sample(s) was submitted, at which time the anatomical pathologist
had access to the history of the dog and the suspected diagnosis and
therefore were not blinded. A presumptive diagnosis of postoperative
pancreatitis was made in dogs based on clinical signs of abdominal
pain, nausea, vomiting, and anorexia, as well as increased serum
canine pancreatic-specific lipase (cPL) concentration and diagnostic
imaging. In the previous literature, such a diagnosis is usually based on
clinical impression of the attending clinician, as neither serum cPL nor
diagnostic imaging, alone or in combination is completely reliable in a
dog that has undergone partial pancreatectomy in the preceding
days.13 In all cases, postoperative ileus as a cause of similar clinical
signs was excluded based on documentation of peristalsis on abdomi-
nal ultrasonography. Analgesia was adjusted in dogs in which opioid
treatment was thought to have contributed to the clinical signs.
2.4 | Outcome measures
The primary outcome measures of the study were time to relapse of
clinical signs (time to progression) and time to death (survival time).
For time to relapse, the time in days between surgery and the first
report of clinical signs of recurrent hypoglycemia was calculated from
the clinical records. For time to death, the time between surgery and
death was calculated, again based on clinical records, and cases were
included whether they died or were euthanized. The main secondary
outcome measure studied was development of postoperative DM,
defined as persistent hyperglycemia requiring long-term (>9 days)
insulin treatment. This time frame was elected as previous human
studies suggest transient hyperglycemia resolves after 9 days in 90%
of human patients after pancreatectomy.18
2.5 | Statistical analysis
Statistical analyses were performed with 2 computer software pack-
ages (Stats Direct version 3.0.171; Stats Direct Ltd. JMP version
14.3.0, SAS Institute Inc.) and P < .05 was chosen to determine statis-
tical significance, with 2-sided analyses used throughout. Cox propor-
tional hazards models were created to determine which variables
were associated with time to relapse of clinical signs and time to
death. For time to relapse, the time in days between the surgery and
the first report of clinical signs was calculated, again from clinical
records. Associated variables were assessed both in terms of “all-
cause mortality” and deaths related only to the insulinoma. Variables
tested included institution, breed, age, sex, neuter status, presence of
clinical signs, duration of clinical signs before diagnosis, weight at pre-
sentation, blood glucose concentration at presentation, serum insulin
concentration at presentation, insulin:glucose ratio at presentation,
tumor size, location of tumor within the pancreas, WHO stage, postop-
erative glycemic status, and occurrence of postoperative complications.
To account for possible clustering as a result of the multicentered
nature of the study, institution was included as a fixed effect in all ana-
lyses; for this, dummy variables were created for institution 2 and
institution 3, with institution 1 as the reference category. Continuous
explanatory variables tested included age (in months), body weight at
presentation (in lb), duration of clinical signs before diagnosis (in days),
blood glucose concentration (in mg/dL), serum insulin concentration
(in mIU/L), insulin:glucose ratio (in mU/mg), and tumor size (in mm).
Categorical variables were tested in a binary format, with a single binary
variable used for sex (male: 1; female: 0) and neuter status (neutered: 1;
intact: 0). Single binary variables (present: 1; absent: 0) were also used
both for individual clinical signs (seizures, ataxia, weakness, collapse)
and for postoperative complications (all complications, diabetes mellitus
only, and suspected pancreatitis only). For breed, separate binary vari-
ables were created for the 3 most popular breeds (mixed breed, boxer,
and West-Highland white terrier) whereas, for WHO stage, a binary
variable was created for dogs classed as stage II or III (with stage 1 used
as the reference category). A similar approach was used for location of
the tumor within the pancreas (left lobe, right lobe or body, with
left lobe as the reference category) and postoperative glycemic
status (hypoglycemia, normoglycemia, and hyperglycemia, with nor-
moglycemia as the reference category).
Initially, each variable was tested separately using simple regression.
Multiple logistic regression models were then built, which initially
included the variables identified as P < .1 on simple regression analysis.
Competing models were tested in a backward and forward stepwise
fashion, with additional of removal of variables, and the best fit model
was chosen using the corrected Akaike Information Criterion (AICc) and
Bayesian Information Criterion (BIC). With this approach, if removal of
any effect yielded amodel with lower AICc and BIC, the variablewith the
least effect was removed, until the model with the smallest AICc and BIC
was found. Contingency tables were used to assess the independence of
each factor comparedwith other factors in themodel. Log(−log[survival])
versus log(time) plots were visually inspected to confirm that propor-
tional hazards assumption was not violated for each explanatory variable
in the final model. Results are expressed as risk ratios (RR), alongwith the
associated 95% confidence interval (95%CI), and P-value.
Simple logistic regression was used to determine associations
between the development of DM postoperatively and the variables
described earlier, with the exception of postoperative glycemic status
given its direct relationship to the outcome variable. For each variable,
odds ratios (OR), Wald-based 95% confidence intervals (95% CI), and
the associated P-value (based upon the Wald Chi-square test) were
calculated. Model fit was assessed by calculating McFadden's pseudo
R2 value (the proportion of the total uncertainty that is attributed to
the model fit, defined as the ratio of the difference to the reduced
negative log-likelihood values), the area under receiver operating char-
acteristic curves (where a value of 1.0 indicates a perfect fit, whereas
a value near 0.5 indicates that the model cannot discriminate among
groups), and the lack-of-fit test from the “Fit Model” platform of the
computer software (also known as the “goodness of fit test,” which
indicates whether the model fits the data). In a similar manner to that
used with the survival analysis, multiple regression models were built
for factors identified as P < .1 on simple regression analysis, with com-
peting models tested in a backward and forward stepwise fashion
using AICc and BIC.
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3 | RESULTS
3.1 | Animals
A total of 49 dogs underwent surgery and were diagnosed with
insulinoma by histopathology at 1 of the 3 referral centers during the
time period of the study. One dog was excluded because of a pre-
existing diagnosis of DM. Therefore, 48 dogs were finally included in
the study (Table 1) with 27 male dogs (57%) and 21 female dogs (43%).
The median age at diagnosis was 7.8 years (range 4 to 11 years). Of the
27 male dogs, 21 (78%) were neutered and 6 (22%) were intact; of the
21 female dogs, 20 (95%) were neutered and 1 was intact (5%). Breeds
represented included crossbreed (9; 19%), boxer (8; 17%), West High-
land white terrier (8; 17%), English springer spaniel (4; 8%), Border collie
(2; 4%), and 1 each of 17 other breeds. The median weight was 58 lb
(26.3 kg), ranging from 15 lb (6.8 kg) to 97 lb (44.0 kg). Eleven (23%)
dogs had weight recorded before the clinical signs developed and at
the time of diagnosis, and weight gain was observed in all but 1 dog.
3.2 | Clinical signs
The median duration of clinical signs was 29 days (range 1-280 days).
Reported clinical signs included generalized (18 dogs; 37%) or focal
(6 dogs; 12%) seizures, ataxia (15 dogs; 31%), weakness (14 dogs;
29%), and collapse (12 dogs; 25%). Forty-four dogs (92%) had signs
suggestive of neurological dysfunction (as detailed individually earlier).
The 4 dogs (8%) without signs of neurological dysfunction presented
with nonspecific signs, predominantly lethargy.
3.3 | Laboratory testing
Blood glucose concentration was measured in all dogs at the time of pre-
sentation and hypoglycemia was defined as a blood glucose concentration
less than 60 mg/dL (3.3 mmol/L). Forty-four dogs (92%) were hypoglyce-
mic, whereas the remaining 4 dogs (8%) dogs had a low-normal blood glu-
cose concentration. Median blood glucose concentration was 34 mg/dL
(1.8 mmol/L) (range 21-58 mg/dL [1.2-3.2 mmol/L]) for hypoglycemic
dogs, and 61 mg/dL (3.4 mmol/L) (range 60-67 mg/dL [3.3-3.7 mmol/L])
for normoglycemic dogs. Serum insulin concentration was measured in
42 dogs (87%); median insulin concentration was 36.9mIU/L (range 9-29).
The insulin:glucose ratio was suggestive of insulinoma (>30 mU/mg)
in 20 dogs (42%) cases. Fructosamine concentration was measured in
7 (15%) dogs, 2 of which had concentrations below the reference interval,
and the remaining 5 had concentrations within the reference interval. The
median fructosamine concentrationwas 255 μmol/L (range 225-295).
3.4 | Staging and surgical procedures
Contrast-enhanced thoracic and abdominal CT was performed in
43 dogs (90%). Findings included pancreatic nodules of varying size
(42), loco-regional lymphadenomegaly (27), and hepatic nodules (3).
In 5 dogs (12%) that were diagnosed with presumed metastatic
lesions based on CT findings (regional lymphadenopathy and
hepatic nodules), these changes were benign based on histopathol-
ogy; in 7 dogs (16%) pancreatic or loco-regional metastatic
lesions were missed on CT; in 1 dog, no pancreatic lesion was seen
but a pancreatic mass was identified during exploratory celiotomy,
which was performed because of the clinical suspicion of
insulinoma. The remaining 5 dogs (10%) had thoracic and abdominal
radiography and abdominal ultrasonography, which identified a
pancreatic mass. Based on WHO staging, 16 dogs (33%) were
TABLE 1 Signalment and clinical signs for the dogs in the study
(mean values for age, body weight, duration of signs, blood glucose,
serum insulin, and insulin:glucose ratio)
Variable
Institution
1 UK
Institution
2 UK
Institution
3 Italy
Number 25 12 11
Age (months) 101 82 100
Sex 14 M 11 F 9 M 3 F 4 M 7 F
Breed 7 Cross breed 3 WHWT 3 WHWT
4 Boxer 2 ESS 3 Boxer
2 WHWT 1 Boxer 1 Cross breed
2 ESS 1 Cross breed 1 AST
2 Border Collie 1 GSD 1 Belgian
1 Greyhound 1 Labrador shepherd
1 Irish Setter 1 Golden
Retriever
1 Istrian
hound
1 GWHP 1 JRT 1 Lhasa Apso
1 YSD 1 Rottweiler
1 Bearded
Collie
1 GSP
1 Lurcher
1 FCR
Bodyweight (kg) 60.2 (27.3 kg) 58.2 (26.4 kg) 57.3 (26 kg)
Duration of signs
(days)
42 12 60
Seizures 6 8 3
Ataxia 5 4 4
Weakness 10 2 2
Collapse 6 2 2
Blood glucose
(mg/dL)
36 (2 mmol/L) 35 (1.9
mmol/L)
36 (2 mmol/L)
Serum insulin
(mIU/L)
31.7 44.5 37.2
Insulin: glucose
(mU/mg)
0.9 1.8 0.7
Abbreviations: AST, American Staffordshire terrier; ESS, English springer
spaniel; F, female; FCR, Flat-coated retriever; GSP, German shepherd dog;
GWHP, German wirehaired pointer; JRT, Jack Russell terrier; M, male;
WHWT, West Highland west terrier; YSD, Yugoslavian shepherd dog.
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stage I, 28 dogs (58%) were stage II, and 4 dogs (8%) were stage III
(Table 2).
A midline celiotomywas performed in all dogs. In 4 dogs (8%), a vis-
ible distinct mass was not present; however, palpation of the pancreas
revealed nodular thickening consistent with possible neoplastic tissue,
which was subsequently excised. Assessment of the regional lymph
nodes and other intraabdominal organs was performed: if any evidence
of metastatic disease was suspected, local lymphadenectomy and (in 4
cases) partial liver resection were performed. Local lymph nodes were
only excised if there was evidence of a gross abnormality (eg, change in
color, size, shape, or consistency) or a concern of metastasis based on
diagnostic imaging (eg, contrast uptake).
All samples were submitted for histopathological examination. Of
all 48 dogs, 16 (33%) underwent partial pancreatectomy alone, excision
of local lymph nodes was required in 28 dogs (58%), whereas 4 dogs
(8%) underwent resection of distant metastatic lesions (partial liver
lobectomy). A single pancreatic mass was present in all but 1 dog,
which had 2 lesions, 1 of which was identified as a pancreatic adenoma
on histopathological examination. Tumor size was assessed in 46 dogs
(96%) with 34 measuring <20 mm (range 3-18 mm), 10 measuring
20-39 mm and 2 measuring >40 mm (42 and 50 mm, respectively).
Pancreatic lesions were identified in the left limb in 24 dogs (51%), in
the right limb in 16 dogs (34%) and in the body in 7 dogs (15%). In
1 dog the location of the tumor was not stated in the medical record.
3.5 | Postoperative complications
Postoperative care consisted of regular assessment of blood glucose
concentration at the time of completing surgery and every 4 hours
thereafter, or more frequently if there was a clinical indication.
For those dogs that developed hyperglycemia postoperatively,
TABLE 2 Surgical findings, postoperative complications and
survival for the dogs in the study
Variable
Institution
1 UK
Institution
2 UK
Institution
3 Italy
Stage
I 10 4 2
II 13 7 8
III 2 1 1
Tumor size (mm) 16 11 12
Tumor location
Left lobe 13 7 4
Body 2 1 2
Right Lobe 9 4 5
Postoperative glycemic status
Hypoglycemia 4 1 6
Normoglycemia 11 6 4
Hyperglycemia 10 5 1
Postoperative complications
All complications 10 2 2
Diabetes mellitus 6 2 1
Suspected
pancreatitis
5 0 0
Time to relapse (days) 365 270 1
Time to death (days)
All cause 392 616 180
Insulinoma-related 140 616 180
TABLE 3 Final multiple Cox regression models for time to relapse
and time to death
Parameter Risk ratio 95% CI* P value
Time to relapse
Institution
1 1.000 - -
2 1.17 0.46-3.00 0.74
3 1.14 0.36-3.67 0.82
Stage
I 1.00 - -
II and III 3.75 1.40-10.04 <0.001
Postoperative glycemic status
Hypoglycemia 4.54 1.63-12.61 0.0044
Normoglycemia 1.00 - -
Hyperglycemia 0.32 0.16-0.97 0.045
Suspected post-op pancreatitis 6.72 1.50-30.21 0.013
Time to death (insulinoma-related)
Institution
1 1.000 - -
2 1.21 0.45-3.30 0.71
3 0.81 0.26-0.54 0.72
Stage
I 1.000 - -
II and III 2.64 1.02-6.86 0.045
Postoperative glycemic status
Hypoglycemia 4.96 1.69-14.50 0.0035
Normoglycemia 1.00 - -
Hyperglycemia 0.70 0.24-2.00 0.50
Suspected post-op pancreatitis 11.84 2.27-61.86 0.0034
Time to death (all cause)
Institution
1 1.000 - -
2 0.75 0.29-1.90 0.54
3 0.61 0.21-1.79 0.36
Stage
I 1.000 - -
II and III 2.26 0.95-5.36 0.064
Postoperative glycemic status
Hypoglycemia 4.41 1.58-12.28 0.0046
Normoglycemia 1.000 - -
Hyperglycemia 1.24 0.49-3.13 0.65
Suspected post-op pancreatitis 7.55 1.87-30.43 0.0045
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short-acting insulin was administered; dogs with persistent hypergly-
cemia characterized by over 48 hours of hyperglycemia were trans-
itioned to long-acting insulin (porcine lente) as required. Dogs that
remained hypoglycemic (11; 23%) for longer periods of time (ie, sev-
eral days) were treated with a 5% dextrose solution and, when there
was hypoglycemia persisting for over 1 week postoperatively, medical
management with prednisolone alone or prednisolone and diazoxide
was started.
Sixteen of the 48 dogs (33%) developed postoperative hyperglyce-
mia, of which 9/48 (19%) required long-term administration of exoge-
nous insulin, and 7/48 (15%) had transient hyperglycemia. Three (3/48;
6%) of the dogs with postoperative hyperglycemia had suspected
TABLE 4 Logistic regression to determine factors associated with postoperative diabetes mellitus
Parameter R2 AUC Lack of fit Odds ratio 95% CI* P value
Age (months) 0.118 0.694 0.721 0.99 0.95-1.03 .64
Institution 0.113 0.672 NC
1 1.00
2 0.63 0.11-3.73 .61
3 0.00 - .99
Breed
Mixed breed 0.113 0.681 0.791 1.15 0.18-7.58 .88
Boxer 0.178 0.738 1.000 0.00 - 1.00
WHWT 0.146 0.684 0.046 3.78 0.44-32.72 .23
Sex 0.168 0.773 0.093
Female 1.00 -
Male 0.91 0.05-1.47 .13
Neuter status 0.114 0.673 0.834
Intact 1.00 -
Neutered 1.19 0.11-12.69 .88
Body weight (lb) 0.196 0.772 0.839 0.93 0.85-1.01 .06
Duration of signs (days) 0.119 0.696 0.440 1.00 0.98-1.01 .62
Clinical signs
Seizures 0.125 0.716 0.076 0.51 0.07-3.42 .50
Ataxia 0.128 0.709 0.993 2.00 0.37-10.83 .42
Weakness 0.140 0.716 0.377 2.49 0.48-13.04 .28
Collapse 0.146 0.733 0.866 0.29 0.03-2.75 .23
Glucose at diagnosis 0.138 0.730 0.834 0.49 0.12-2.10 .30
Insulin at diagnosis 0.131 0.725 0.567 1.00 0.99-1.01 .58
Insulin: glucose 0.125 0.743 0.556 1.04 0.78-1.40 .79
Stage 0.113 0.681 0.806
I 1.00 -
II and III 1.05 0.21-5.13 .96
Tumor size (mm) 0.121 0.702 0.957 0.98 0.90-1.06 .56
Tumor location 0.27 0.722 0.791
Left lobe 1.000 -
Body 1.61 0.12-21.98 .72
Right lobe 0.57 0.09-3.53 .55
Suspected postoperative pancreatitis 0.132 0.703 NC 4.11 0.56-29.96 .16
Note: R2: McFadden's pseudo R2 value, the proportion of the total uncertainty that is attributed to the model fit, defined as the ratio of the difference to
the reduced negative log-likelihood values. AUC: area under receiver operating characteristic curve, which is an indicator of the goodness of fit for the
model; a value of 1 indicates a perfect fit, whilst a value near 0.5 indicates that the model cannot discriminate among groups. Lack of fit: lack of fit (also
known as goodness of fit) test, which indicates whether the model fits the data; the value indicated is the P-value for the test, with small values indicating
a significant lack of fit. 95% CI: Wald-based 95% confidence intervals of the odds ratio for each variable. P-value: determined by the Wald Chi square test.
NC: Lack of fit could not be computed for this model.
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pancreatitis and systemic inflammatory response syndrome (SIRS) and
died within 48 hours of surgery.
Median survival time (MST) of dogs with persistent DM was
224 days (range 28-1680 days) and all required long-term insulin
treatment. MST of dogs with transient hyperglycemia was 420 days
(range 224-1260 days). MST of the 11/48 dogs (23%) with postopera-
tive hypoglycemia was 180 days (range 14-672 days).
Within 48 hours of surgery, 5/48 dogs (10%) developed suspected
postoperative pancreatitis, of which 3/48 (6%) met the criteria for SIRS.
The survival time of dogs with concurrent SIRS was less than or equal
to 2 days.
Insulinoma progression was documented in 20/48 dogs (42%),
with a median disease-free interval of 275 days (range 1-980 days).
3.6 | Factors associated with time to recurrence
Relapse occurred in 20/48 dogs (42%). Treatment postrelapse was
variable, possibly including additional surgery, medical treatment (pred-
nisolone either given alone or in combination with diaxozide) or eutha-
nasia based on owner discretion. Given the diversity of treatment
received, differences in treatment were not explored statistically. Using
Cox's proportional hazards regression analysis (Table 3), stage, postop-
erative glycemic status, and the suspected development of pancreatitis
postoperatively were all positively associated with recurrence. The risk
of relapse was greater for dogs classified as either stage II or III
(RR 3.75, 95% CI 1.40-10.04) compared with stage I, for dogs that
developed postoperative hypoglycemia (RR 4.54, 95% CI 1.63-12.61),
and for dogs that developed suspected postoperative pancreatitis
(RR 6.72, 95% CI 1.50-30.21) although it should be emphasized that
the number affected was small (5 dogs).
3.7 | Factors associated with survival time
Themedian duration of follow-upwas 15 months (ranging from 1month
to 3 years). During this period 34 dogs died or were euthanized, with
13 dogs (38%) dying or being euthanized as a result of insulinoma
recurrence. Cause of death in the other dogs included disseminated
hemangiosarcoma, uncontrolled seizures (intracranial neoplasm), hyper-
adrenocorticism, or other reasons. Using Cox's proportional hazards
regression analysis (Table 3), stage, postoperative glycemic status, and
the development of suspected postoperative pancreatitis were all associ-
atedwith the risk of dying from insulinoma. The risk of deathwas greater
for stage II or III dogs (RR 2.64, 95% CI 1.02-6.86) compared to stage
I. When analyzing the impact of the postoperative glycemic status, the
risk of recurrence was greater for dogs that remained or became hypo-
glycemic within the first 24 hours (RR 4.96, 95% CI 1.69-14.50) com-
pared with normoglycemic dogs, but there was no difference between
those that developed hyperglycemia and normoglycemic dogs (RR 0.70,
95% CI 0.24-2.00). Dogs that developed suspected postoperative pan-
creatitis had a greater risk of recurrence compared with those that did
not (RR 11.84, 95% CI 2.27-61.86). However, it should again be empha-
sized that the number of affected dogs was small (5), and also that the
3 dogs developing suspected pancreatitis and SIRS that died postopera-
tively were included in the survival analysis. Similar results were seen
when all-cause mortality was assessed (Table 3).
3.8 | Factors associated with postoperative DM
Logistic regression was used to determine factors associated with the
odds of developing persistent DM in the postoperative period (Table 4).
Using simple regression analysis, there were no factors that were signif-
icant in their own right and, given that none qualified (at P < .1) for
inclusion in multiple regressionmodeling, nomodels were built.
4 | DISCUSSION
In this study, the postoperative complications and survival times of
dogs undergoing surgical management of insulinoma were assessed,
alongwith factors associated with relapse and survival. Stage of the dis-
ease and postoperative hypoglycemia were associated with a greater
odds of relapse and decreased survival time. Although there was also
an association with suspected pancreatitis, the clinical importance of
this is not clear. Such information will be valuable to clinicians because
they could be taken into account when discussing prognosis with cli-
ents. Postoperative diabetes mellitus developed more commonly than
previously reported, and all affected dogs required on-going exogenous
insulin treatment. No factors were identified that might be useful pre-
dictors of postoperative DM.
Various clinical signs are reported with insulinoma, most of them
because of the resulting neuroglycopenia.19 In this study, 44 dogs
(92%) presented with neurological signs; the most common of which
were generalized and focal seizures, although ataxia, weakness, and
collapse were also seen (Table 1). Hypoglycemia was also identified in
44 dogs (92%), with the remaining dogs having a blood glucose concen-
tration within the reference interval. Insulin:glucose ratio is reported to
aid in the diagnosis of insulinoma in dogs, although poor sensitivity and
specificity are reported.20 Some studies suggest a ratio over 30 μIU/L is
diagnostic for insulinoma,21,22 whereas others have suggested poor
sensitivity,1,21 and associations between abnormal insulin:glucose
ratios and other causes of hypoglycemia have been reported.5,21,22
Given that only 20 dogs (42%) in the current study had an insulin:glu-
cose ratio > 30 mIU/L, our findingsmight question the suitability of this
test for the diagnosis of insulinoma.
Intraoperatively, tumors were localized in the left pancreatic limb
(51%), right pancreatic limb (34%), and pancreatic body (15%; Table 2).
This is in agreement with what it has been previously reported, pancre-
atic lesions are more commonly located in the limbs (left: 44%, right:
35%) and less frequently in the body (14%).6 In all cases, pancreatic
tumorswere resected and therewas no significant association between
the location of the pancreatic tumor and time to relapse or survival
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time. Tumor size has previously been reported to be a negative prog-
nostic indicator, and larger tumors are associated with shorter survival
in human studies.23 In this study, there was no association between
tumor size and prognosis.
Close monitoring of blood glucose concentration is recommended
after partial pancreatectomy for insulinoma.13 Persistent postoperative
hypoglycemia has been associated with a poorer prognosis, because it is
suggestive of an incompletely excised tumor or the presence of metasta-
sis. Postoperative hyperglycemia after partial pancreatectomy for treat-
ment of insulinoma is commonly described.22 Although its duration and
significance in humanmedicine is unclear, most studies suggest it is usually
transient and self-resolves in 3 to 9 days.18 In a recent study in people, the
prevalence of hyperglycemia was 36%,24 and no significant difference in
age, sex, tumor size, or surgical approach were noted between human
patients with normoglycemia and those that were hyperglycemic during
the postoperative period.24 In dogs, postoperative transient hyperglyce-
mia has been commonly recognized, and it has been associatedwith a bet-
ter prognosis,12 whereas the development of permanent DM is believed
to be uncommon.7 In our study, postoperative hyperglycemia was identi-
fied in 16 dogs (33%), of which, 7/48 had transient hyperglycemia and
9/48 developed persistent DM. The percentage of dogs that developed
hyperglycemia requiring chronic exogenous insulin (19%) was greater than
previously reported, and similar to the reported rate in humans (23%).15
Transient hyperglycemia was identified as a positive prognostic factor in
this study as previously reported,25 supported by amedian survival time of
420 days compared to 224 days for those dogs with DM and 180 days
for dogs with postoperative hypoglycemia. DM occurred in 19% of cases,
which is higher than in previous reports where a prevalence of approxi-
mately 10% was reported.7 This finding suggests that permanent insulin
treatment might be required for a substantial number of dogs undergoing
surgery. Further, dogs developing DM had decreased median survival
times when compared to dogs with transient hyperglyemia (224 days ver-
sus 420 days, respectively). However, the fact that no variables were iden-
tified that were associatedwith its development suggests that it is difficult
for clinicians to predict inwhich cases it will occur.
Pancreatitis is another well-recognized complication of pancreatec-
tomy, with 10% of dogs reportedly affected.1,9,13,25,26 In this study, 10%
of dogs had suspected postoperative pancreatitis and, when this devel-
oped, its presence was negatively associated with survival, most notably
in dogs with clinical findings consistent with SIRS. This effect on survival
was strong, despite the small number of dogs (5) affected. Nonetheless,
it should be emphasized that pancreatitis was not definitely proven, as
this would be difficult to achieve in dogs that had recently undergone
pancreatectomy. Diagnosis was largely based on clinical signs (abdominal
pain, nausea, vomiting, and anorexia), with possible addition of increased
CPL concentration, supportive diagnostic imaging findings or both. As
the result, suspected postoperative pancreatitis might have been under-
or over-diagnosed. For example, the clinical signs in some cases could
have been because of postoperative ileus or an adverse effect of opioid
analgesia, however attempts were made to exclude this where possible.
Median survival time for dogs with insulinoma undergoing surgical
treatment was 372 days, which is equivalent to median survival times
previously reported.9,10 Stage of the disease can be determined preoper-
atively and has been reported to be a good prognostic factor in dogs
with insulinoma.21 Dogs with stage I disease have been reported to have
the longest disease-free interval, whereas those with stage III disease
have significantly shorter survival times.21 Similarly, in this study, stage of
the disease was associated with survival time, most notably for dogs with
either stage II or stage III disease. Dogs with stage I disease had a median
survival time of 652 days, whereas dogs with stage II or III disease had a
median survival time of 320 days. One limitation of this study was the
fact that few dogs had stage III disease and, as a result, these dogs could
not be assessed separately.
This study has several limitations. First, although this is technically the
largest study of dogs undergoing surgical management of insulinoma, the
number of cases included was still small and only 6 more than a previous
study.25 Second, given the retrospective and observational design, statisti-
cal significance does not necessarily imply causation. Further, for some
variables such as suspected postoperative pancreatitis, the number of
dogs affected was small and, as a result, the findings should be interpreted
cautiously. As discussed above, the diagnosis was only presumptive and
the clinical findings might have arisen for other reasons such as abdominal
pain postsurgery, increased serum cPL as a result of surgery. As such,
suspected postoperative pancreatitis could have been over or, more likely,
under diagnosed, particularly considering it was only documented in 1 of
the 3 centers included in the study. Whereas suspected postoperative
pancreatitis had a statistically significant effect on time to relapse and sur-
vival based on the data, the number of affected dogs was small (5) and fur-
ther work would be required to determine whether suspected
postoperative pancreatitis has a genuine effect on outcomemeasures.
Third, both the retrospective nature and also the fact that it was a
multicenter study would likely lead to inconsistencies in diagnostic
approach and management, as well as in the data recorded (in particular
postoperative care). Fourth, the median duration of follow-up was
15 months (ranging from 1 month to 3 years) and, therefore, the low rate
of recurrence for this disease might be an underestimate. One specific
concern would be that there might have been insufficient time for some
dogs to relapse, most notably those dogs with a short follow-up time.
However, there was no significant difference in dogs that died versus
those that did not (Mann-Whitney P = .85 for insulinoma-related death;
P = 0.71 for all-cause mortality). This suggests that the duration of follow-
up in the dogs that did not relapse in their follow-up was not considerably
shorter than in those that did. Further, time to relapse or censoring was
significantly shorter in dogs that relapsed than in dogs that did not (Mann-
Whitney P = .02); this would suggest that the short follow-up times almost
invariably occur in dogs that relapse quickly (as supported by the statistics
of time to death or censoring or time to relapse). Indeed, of the 16 dogs
with a follow-up time of <100 days, all but 1 had relapsed within their
follow-up period. Finally, because this was a referral population, it might
not be fully representative of cases seen in primary care practice. That said,
because surgical management of insulinoma is usually undertaken in refer-
ral centers, these findings are likely to be helpful for primary care veterinar-
ians when discussing possible outcomes of referral surgical management
with owners.
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In summary, this study examined postoperative complications, relapse
and survival times of dogs undergoing surgical management of insulinoma.
Stage of the disease and postoperative hypoglycemia were associated
with a greater odds of relapse and decreased survival time. Although there
was also an association with suspected pancreatitis, the clinical importance
of this is not clear. Development of DM after surgery for insulinoma might
be more common than previously reported, and affected dogs have a
worse prognosis than dogs with only transient hyperglycemia. Such infor-
mation might aid clinicians in predicting prognosis in the future.
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